Emerging biotech Early-stage, NIH SBIR-backed spin-off from MSK with focused development of targeted cancer diagnostics, signaling a potential need for specialized research tools, CRO partnerships, and early-stage commercialization support.

New York R&D Established R&D footprint in New York City with recent federal funding, presenting opportunities to offer local contract research services, logistics, and on-site collaboration capabilities to accelerate product milestones.

Resource constraints Very small team (0-1 employees) implies high dependence on external vendors for analytics, manufacturing, clinical validation, and regulatory support; targeted outreach for partnerships and scalable service offerings could be impactful.

Digital footprint Tech stack includes Wix, Google Cloud, and cloud monitoring, indicating openness to hosted SaaS solutions, cloud-based data management, and lightweight integrative tools that can be offered as secure, compliant workflows.

Growth potential Revenue under one million with SBIR backing suggests upcoming scaling needs, including pilot programs, validation studies, funding stewardship, and strategic alliances with larger providers or device/diagnostics manufacturers.